Whether gene editing technology will advance enough to treat or cure the majority of inherited genetic conditions.
Scope: CRISPR-Cas9 advances, clinical trials, regulatory approval, delivery mechanisms, ethics
CRISPR gene editing technology has shown immense promise in preclinical and early-stage clinical trials for various genetic diseases. Currently, several ex-vivo (cells edited outside the body) CRISPR therapies are in advanced clinical stages, particularly for blood disorders. In-vivo (direct editing within the body) applications are more challenging due to delivery limitations and potential off-target effects but are also seeing progress, especially in conditions affecting the liver or eyes. Regulatory bodies are establishing frameworks, but the long-term safety and efficacy, as well as ethical considerations, remain central to its widespread adoption.
What is the real reason for the sudden, unexplained "Great Silence" from the James Webb Space Telescope?
75%JWST went dark for 72 hours and NASA's explanations keep changing. Conspiracy theories range from a major discovery cover-up to a catastrophic failure.
Did COVID-19 leak from a lab?
75%The debate over SARS-CoV-2 origins — natural zoonotic spillover vs. Wuhan Institute of Virology lab leak.
Will room-temperature superconductors be achieved by 2030?
10%Monitoring progress toward room-temperature, ambient-pressure superconductors. Tracking LK-99 aftermath, hydride research under extreme pressures, and novel material discoveries.
Will nuclear fusion become commercially viable by 2035?
45%ITER, private companies (Commonwealth Fusion, TAE) — when will fusion deliver net energy to the grid?
Will lab-grown organs end the transplant crisis?
75%Whether bioengineered organs from stem cells or 3D bioprinting will eliminate organ donor shortages.
Will we find extraterrestrial life by 2040?
70%Whether definitive evidence of life beyond Earth — microbial or intelligent — will be discovered within the next 15 years.